Blood Test Checks for Lung Cancer Traces After Surgery
Tests a blood test for leftover lung cancer in adults after surgery removes the tumor.
Plain-language title generated from the registry record
Registry title: Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
Key facts
- Where
- Toronto, CanadaSee the 3 sites
Where in Canada
- Michael Garron HospitalToronto, CanadaTaking people
- St. Joseph's Health CentreToronto, CanadaTaking people
- University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT05254782
- Record updated
- 9 June 2026
- Original description
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.Read full original descriptionShow less
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Inclusion: Age ≥ 18 years; Ability to provide written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; T1-T4 (T3,T4 multifocal) N0M0 NSCLC who are planned for complete surgical resection; Tumour size must be at least 1 cm (unidimensional) and have at least some solid component on imaging; Surgical tumour formalin-fixed, paraffin-embedded (FFPE) specimens for ctDNA studies are required.
Exclusion: Prior radiation, surgery or chemotherapy for the current diagnosis of NSCLC is not permitted; Incomplete surgical resection. Participants who had pre-operative ctDNA samples taken but subsequently do not have a complete surgical resection would not qualify for post-operative ctDNA testing; Concurrent enrolment in a therapeutic study using drug or radiation therapy. Enrolment in observational, diagnostic or studies of novel surgical techniques will be allowed; Concurrent active malignancy or other invasive malignancy within previous 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition; Pregnancy.